Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 10/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167279 | 0.82 | FFAR1 (0.45) | CYP1A2CYP3A4CYP2C19MAPK1CYP2C9 | |
| SCHEMBL5613146 | 0.82 | PIK3CA (0.45) | CYP3A4CYP2C9LMNAMEN1KMT2A | |
| SCHEMBL5612905 | 0.80 | METAP2 (0.61) | CYP1A2CYP3A4CYP2C19MAPK1HSD17B10 | |
| SCHEMBL6165618 | 0.76 | INSR (0.46) | MAPK1HSD17B10KDM4ETSHRLMNA | |
| SCHEMBL5612752 | 0.75 | METAP2 (0.46) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5613128 | 0.73 | KDM4E (0.46) | CYP1A2MAPK1HSD17B10HIF1AKDM4E | |
| SCHEMBL30287924 | 0.73 | HIF1A (0.74) | MAPK1HIF1AKDM4ETSHRMEN1 | |
| SCHEMBL10388545 | 0.73 | HIF1A (0.74) | MAPK1HIF1AKDM4ETSHRMEN1 | |
| SCHEMBL5612904 | 0.73 | BRD4 (0.50) | HIF1AKDM4EMEN1KMT2AMAPT | |
| SCHEMBL5612898 | 0.72 | HPGD (0.53) | CYP1A2CYP3A4CYP2C19MAPK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | claimed |
| EP-1434772-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040192914-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | claimed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | disclosed |
| EP-1434772-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20040192914-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | HTR5A, HTR2C, HTR3C | CYP1A2 406/4885CYP3A4 294/4885CYP2C19 240/4885 |
| US-20040192914-A1 | Compounds and methods | METAP2, METAP1, DNPEP | CYP1A2 1882/4885CYP3A4 2373/4885CYP2C19 1557/4885 |
| US-20050143578-A1 | Compounds and methods | METAP2, METAP1, DNPEP | CYP1A2 1632/4885CYP3A4 2451/4885CYP2C19 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.